OncoZenge's Collaboration with UCLA
OncoZenge AB (publ) has announced an exciting new collaboration with the University of California, Los Angeles (UCLA). This partnership will focus on a patient engagement study designed to understand better the needs of individuals managing oral mucositis pain, particularly in the context of the emerging therapeutic BupiZenge™.
Goals of the Study
The primary aim of this study is to leverage UCLA's expertise in oncology and radiation therapy. By engaging both patients and clinicians, OncoZenge hopes to gather comprehensive insights that can steer the clinical development of BupiZenge™. This innovative, non-opioid lozenge aims to provide localized relief from the severe oral pain often encountered during cancer treatments, addressing a critical gap in the options currently available.
Stian Kildal's Perspective
Stian Kildal, the CEO of OncoZenge, expressed enthusiasm about the collaboration, stating, "We are excited to partner with UCLA, a world-leading institution in cancer research and patient care. This collaboration not only enhances our understanding of patient experiences through the engagement study but also opens doors for navigating the regulatory landscape for a potential Investigational New Drug (IND) application. We are getting closer to introducing BupiZenge™ to patients in the US market."
UCLA's Contribution
Dr. Robert K. Chin, a Radiation Oncologist at UCLA Health, highlighted the significance of this partnership, noting the challenges faced by cancer patients suffering from oral mucositis. He voiced optimism that the patient engagement study would elevate patient voices and explore the innovative solutions that BupiZenge™ could provide, potentially leading to advancements in clinical care in the US.
Broader Implications for Patient Care
This new initiative reflects OncoZenge's ongoing preparations for a Phase III trial in Europe while simultaneously reinforcing the company's commitment to forming partnerships that advance BupiZenge™ across critical markets worldwide. The potential for BupiZenge™ to emerge as a leading treatment for oral pain is significant, especially given the inadequacies of current treatment options available for patients.
Understanding BupiZenge™
BupiZenge™ represents a revolutionary advancement in oral pain management, particularly for those suffering from oral mucositis due to cancer treatments. This lozenge formulation of bupivacaine is designed to offer quick and prolonged pain relief without the adverse effects associated with systemic opioids. OncoZenge is determined to ensure that patients have access to this much-needed treatment option.
Company Contact Details
For those seeking more information, please reach out to Stian Kildal, the CEO of OncoZenge, at mobile: +46 76 115 3797.
About OncoZenge AB
OncoZenge AB is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for oral pain in settings where existing options fall short. Based in Stockholm, Sweden, OncoZenge is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. The company is focused on delivering effective and well-tolerated therapies that improve patients' quality of life.
Frequently Asked Questions
What is the purpose of the collaboration between OncoZenge and UCLA?
The collaboration focuses on a patient engagement study aimed at gathering insights on managing oral mucositis pain and advancing BupiZenge™ for clinical use.
What is BupiZenge™?
BupiZenge™ is an innovative lozenge formulation of bupivacaine developed by OncoZenge, designed to provide localized and sustained relief from severe oral pain associated with cancer treatments.
Who is involved in the patient engagement study?
The study involves collaboration between OncoZenge and experts at UCLA, including clinicians and cancer patients.
What stage is BupiZenge™ currently in?
BupiZenge™ is in the Phase III preparations stage for clinical trials in Europe.
How can patients get involved or learn more?
Patients interested in the study or BupiZenge™ can reach out to OncoZenge for additional information through their designated contact.
